Forte Biosciences Inc. has released its second quarter 2025 financial results. The company reported a net loss of $11.249 million for the quarter, compared to a net loss of $12.511 million for the same period in 2024. The comprehensive loss for the quarter was $11.249 million, showing a slight improvement from the $12.516 million loss reported in the same period last year. The company's general and administrative expenses decreased to $2.96 million for the quarter, down from $7.078 million in the same period of 2024, primarily due to reduced professional and legal expenses. Conversely, research and development expenses increased to $8.6 million, compared to $5.7 million in the previous year, driven by a $3.8 million rise in clinical expenses. Forte ended the quarter with $106.1 million in cash and cash equivalents. The company also completed a public offering in June, selling 5,630,450 shares of common stock and pre-funded warrants, raising net proceeds of $69.9 million. In July, the underwriters exercised their over-allotment option, resulting in additional net proceeds of $1.7 million. Forte continues to advance its FB102 program through clinical trials, with plans to present phase 1b data at the Tampere Celiac Disease Symposium in Finland in September 2025.